Dextromethorphan/quinidine
< Dextromethorphan
| Combination of | |
|---|---|
| Dextromethorphan | Sigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor |
| Quinidine | Antiarrhythmic agent, CYP2D6 inhibitor |
| Clinical data | |
| Trade names | Nuedexta |
| Other names | AVP-923; DXM/quinidine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611048 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | dextromethorphan 11%, quinidine 70-80%. Food has no effect on absorption. |
| Metabolism | Liver, extensive. Dextromethorphan is catalyzed by CYP2D6. Quinidine is metabolized by CYP3A4 and competitively inhibits the metabolism of dextromethorphan to increase and prolong plasma concentrations of dextromethorphan |
| Elimination half-life | dextromethorphan 13h, quinidine 7h |
| Excretion | quinidine 5-20% |
| Identifiers | |
| CAS Number | |
| KEGG | |
Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.
Dextromethorphan/quinidine was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.